- Home
- OPEN vs ARQT Comparison
OPEN vs ARQT Comparison
Compare OPEN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPEN
- ARQT
- Stock Information
- Founded
- OPEN 2014
- ARQT 2016
- Country
- OPEN United States
- ARQT United States
- Employees
- OPEN N/A
- ARQT N/A
- Industry
- OPEN Real Estate
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- OPEN Finance
- ARQT Health Care
- Exchange
- OPEN Nasdaq
- ARQT Nasdaq
- Market Cap
- OPEN 954.6M
- ARQT 1.1B
- IPO Year
- OPEN N/A
- ARQT 2020
- Fundamental
- Price
- OPEN $1.32
- ARQT $13.08
- Analyst Decision
- OPEN Hold
- ARQT Strong Buy
- Analyst Count
- OPEN 4
- ARQT 5
- Target Price
- OPEN $2.23
- ARQT $17.00
- AVG Volume (30 Days)
- OPEN 40.5M
- ARQT 1.9M
- Earning Date
- OPEN 02-27-2025
- ARQT 02-25-2025
- Dividend Yield
- OPEN N/A
- ARQT N/A
- EPS Growth
- OPEN N/A
- ARQT N/A
- EPS
- OPEN N/A
- ARQT N/A
- Revenue
- OPEN $4,939,000,000.00
- ARQT $138,708,000.00
- Revenue This Year
- OPEN N/A
- ARQT $215.24
- Revenue Next Year
- OPEN $20.92
- ARQT $53.63
- P/E Ratio
- OPEN N/A
- ARQT N/A
- Revenue Growth
- OPEN N/A
- ARQT 182.84
- 52 Week Low
- OPEN $1.28
- ARQT $5.38
- 52 Week High
- OPEN $3.71
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- OPEN 35.42
- ARQT 41.94
- Support Level
- OPEN $1.28
- ARQT $13.33
- Resistance Level
- OPEN $1.53
- ARQT $15.09
- Average True Range (ATR)
- OPEN 0.12
- ARQT 0.86
- MACD
- OPEN 0.00
- ARQT -0.16
- Stochastic Oscillator
- OPEN 11.76
- ARQT 6.25
About OPEN Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.